source
- Austria’s new growth fund could further bolster its dynamic biotech innovation economyThe national growth vehicle isn’t biotech‑dedicated, but channeling capital toward life sciences would amplify Austria’s strong research hubs, nondilutive funding landscape and reputation as a cham…BioSpace · 24m ago↗ source
- Scribe Therapeutics launches first gene‑editing IPO in over two years, targeting high‑cholesterol geneScribe Therapeutics, a gene‑editing biotech based in California, announced its initial public offering, the first for a CRISPR‑focused company in more than two years. The company, founded by resea…